ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 431,04
0,00%
Dow Jones
41 938,45
-1,63%
DAX
20 221,34
0,00%
Brent Oil
80,46
-0,19%
Bitcoin
93 418,29
-1,13%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. AnaptysBio Inc (ANAB)

  7. AnaptysBio Inc (ANAB) Actualités

ANAB

AnaptysBio (ANAB)

AnaptysBio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ANAB
DateHeureSourceTitreSymboleSociété
07/01/202523h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
07/01/202515h15GlobeNewswire Inc.Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANABAnaptysBio Inc
18/12/202422h30Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ANABAnaptysBio Inc
11/12/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
11/12/202414h30GlobeNewswire Inc.Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic DermatitisNASDAQ:ANABAnaptysBio Inc
18/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ANABAnaptysBio Inc
15/11/202422h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANABAnaptysBio Inc
14/11/202415h24Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANABAnaptysBio Inc
05/11/202422h27Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ANABAnaptysBio Inc
05/11/202422h19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
05/11/202422h15GlobeNewswire Inc.Anaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
05/11/202422h15GlobeNewswire Inc.Anaptys Announces Participation in November and December Investor ConferencesNASDAQ:ANABAnaptysBio Inc
23/09/202422h16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANABAnaptysBio Inc
29/08/202415h15GlobeNewswire Inc.Anaptys Announces Participation in September Investor ConferencesNASDAQ:ANABAnaptysBio Inc
16/08/202418h07Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:ANABAnaptysBio Inc
14/08/202411h00GlobeNewswire Inc.Anaptys Announces Pricing of $100 Million Underwritten Registered Direct OfferingNASDAQ:ANABAnaptysBio Inc
05/08/202422h25Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANABAnaptysBio Inc
05/08/202422h15GlobeNewswire Inc.Anaptys Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
09/05/202422h15GlobeNewswire Inc.Anaptys Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
09/05/202422h10GlobeNewswire Inc.Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
09/05/202422h05GlobeNewswire Inc.Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli RoyaltiesNASDAQ:ANABAnaptysBio Inc
06/05/202418h59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANABAnaptysBio Inc
24/04/202415h00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:ANABAnaptysBio Inc
11/03/202421h36Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANABAnaptysBio Inc
29/02/202415h15GlobeNewswire Inc.Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual MeetingNASDAQ:ANABAnaptysBio Inc
14/02/202416h01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANABAnaptysBio Inc
31/01/202415h15GlobeNewswire Inc.Anaptys to Present at Guggenheim’s 6th Annual Biotechnology ConferenceNASDAQ:ANABAnaptysBio Inc
27/11/202322h15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:ANABAnaptysBio Inc
07/11/202322h15GlobeNewswire Inc.Anaptys Named a BioSpace 2024 Best Places to Work WinnerNASDAQ:ANABAnaptysBio Inc
02/11/202321h15GlobeNewswire Inc.Anaptys Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
 Showing the most relevant articles for your search:NASDAQ:ANAB

Dernières Valeurs Consultées

LSE
ZF97
Newday Fd 27a
ASX
AJY
Asaplus Resources
USOTC
DFRYF
Avolta (PK)
ASX
AHQDB
Allegiance Coal
LSE
SV51
Nordic 34
LSE
QI63
Morg.st.b.v 25
LSE
FR80
Ang.w.s.f.39
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés